Key facts
- It has raised $22.8M; the latest was Seed Round ($22.3M) in Jan 2025.
- Notable investors include Novo Holdings, BioInnovation Institute, Korys Investments, Aarhus University, Bioqube Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Commit Biologics
- ·The full record, as it builds
Funding rounds
No funding rounds for Commit Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Commit Biologics
Developer of a novel immunotherapy platform intended for the treatment of a variety of cancers. The company's platform specializes in directing to kill tumor cells using b-specific domain antibodies and further refined into the modular technology that can be formatted to target and destroy cancer cells by engaging the body's innate immune response, enabling healthcare professionals to activate the complement component of the immune system to treat cancer and autoimmune diseases.
- Sector
- Healthcare
- HQ
- Aarhus C, Denmark
- Founded
- 2021
- Employees
- 26
- Website
- commitbio.com/
- Ownership
- Privately Held (backing)
Commit Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Commit Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Commit Biologics in its N-PORT filings yet. We sweep new filings monthly.